// App-Quantinova.ai

5056 : Can Activation Induced Cytidine Deaminase Lead to Genetic Instability in Bcr-Abl Negative Myeloproliferative Neoplasms?

Researchers

Presenter

  • Aynur Daglar

Principal Investigators

  • Basak Peker Akadam

  • Veysel Sabri Hancer

  • Yusuf Gelmez

  • Melih Aktan

  • Meliha Nalcaci

  • Akif S. Yavuz

Medical Centers

  • Konya University Medical Faculty, Istanbul, Turkey

  • Department of Internal Medicine, Division of Hematology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey

  • Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul, Turkey

  • Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul, Turkey

  • Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

  • Konya University Medical Faculty, Istanbul, Turkey

  • Department of Immunology, Istanbul University, Institute of Experimental Medicine DETAE, Istanbul, Turkey

  • Rheumatology, Istanbul Bilim University, Istanbul, Turkey

Locations

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Chronic Lymphocytic Leukemia

  • Essential thrombocythemia

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Polycythemia vera

  • Myelodysplastic Syndrome

  • Myelofibrosis

  • Lung Cancer

  • Venous thrombosis

  • Lymphomas

  • Solid malignancies

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • DNA methyltransferase 3 alpha

  • E3 ubiquitin-protein ligase CBL

  • Enhancer of zeste homolog 2

  • Lactate dehydrogenase

  • Suppressor Of Cytokine Signaling 3

  • Tet methylcytosine dioxygenase 2

  • Tumor protein p53

Drug/Treatment

  • L-Tyrosine

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved